Management of acute haemarthrosis in haemophilia A without inhibitors: Literature review, European survey and recommendations

Haemophilia

Volumn 17, Issue 3, 2011, Pages 383-392

  Hermans, C ^a   De Moerloose, P ^b   Fischer, K ^c   Holstein, K ^d   Klamroth, R ^e   Lambert, T ^f   Lavigne Lissalde, G ^g   Perez, R ^h   Richards, M ⁱ   Dolan, G ^j  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e VIVANTES KLINIKUM IM FRIEDRICHSHAIN   (Germany)

^f BICÊTRE HOSPITAL   (France)

^g DEPARTMENT OF NEUROLOGY   (France)

^h HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

ⁱ ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^j QUEEN S MEDICAL CENTRE   (United Kingdom)

more..

Author keywords

Haemarthrosis; Haemophilia; Recommendations; Survey

Indexed keywords

ANTIINFLAMMATORY AGENT;

CLINICAL ASSESSMENT; CLINICAL PRACTICE; EUROPE; HEALTH SURVEY; HEMARTHROSIS; HEMOPHILIA A; HUMAN; JOINT ASPIRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REST; REVIEW; STANDARDIZATION; WEIGHT BEARING;

ACUTE DISEASE; ADULT; BLOOD COAGULATION FACTORS; CHILD; EUROPE; HEMARTHROSIS; HEMOPHILIA A; HUMANS; PAIN; PHYSICAL THERAPY MODALITIES; PRACTICE GUIDELINES AS TOPIC;

EID: 79955133703     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2010.02449.x     Document Type: Review

References (64)

1. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 6: 535-44.
2. Lafeber FP, Miossec P, Valentino LA. Physiopathology of haemophilic arthropathy. Haemophilia 2008; 14(Suppl. 4): 3-9.
3. Roosendaal G, Jansen NW, Schutgens R, Lafeber FP. Haemophilic arthropathy: the importance of the earliest haemarthroses and consequences for treatment. Haemophilia 2008; 14(Suppl. 6): 4-10.
4. Valentino LA, Hakobyan N, Enockson C. Blood-induced joint disease: the confluence of dysregulated oncogenes, inflammatory signals, and angiogenic cues. Semin Hematol 2008; 45(2 Suppl. 1): S50-7.
5. Jansen NW, Roosendaal G, Bijlsma JW, DeGroot J, Lafeber FP. Exposure of human cartilage tissue to low concentrations of blood for a short period of time leads to prolonged cartilage damage: an in vitro study. Arthritis Rheum 2007; 56: 199-207.
6. Jansen NW, Roosendaal G, Bijlsma JW, DeGroot J, Theobald M, Lafeber FP. Degenerated and healthy cartilage are equally vulnerable to blood-induced damage. Ann Rheum Dis 2008; 67: 1468-73.
7. Hooiveld MJ, Roosendaal G, Jacobs KM et al. Initiation of degenerative joint damage by experimental bleeding combined with loading of the joint: a possible mechanism of hemophilic arthropathy. Arthritis Rheum 2004; 50: 2024-31.
8. Ribbans WJ, Giangrande P, Beeton K. Conservative treatment of hemarthrosis for prevention of hemophilic synovitis. Clin Orthop Relat Res 1997; 343: 12-8.
9. Astermark J, Morado M, Rocino A et al. Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors. Haemophilia 2006; 12: 363-71.
10. Palareti G, Leali N, Coccheri S et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348: 423-8.
11. Thumboo J, O'Duffy JD. A prospective study of the safety of joint and soft tissue aspirations and injections in patients taking warfarin sodium. Arthritis Rheum 1998; 41: 736-9.
12. Srivastava A. Dose and response in haemophilia - optimization of factor replacement therapy. Br J Haematol 2004; 127: 12-25.
13. Brown DL, Hardisty RM, Kosoy MH, Bracken C. Antihaemophilic globulin: preparation by an improved cryoprecipitation method and clinical use. Br Med J 1967; 2: 79-85.
14. Honig GR, Forman EN, Johnston CA, Seeler RA, Abildgaard CF, Schulman I. Administration of single doses of AHF (factor VIII) concentrates in the treatment of hemophilic hemarthroses. Pediatrics 1969; 43: 26-33.
15. Britton M, Harrison J, Abildgaard CF. Early treatment of hemophilic hemarthroses with minimal dose of new factor 8 concentrate. J Pediatr 1974; 85: 245-7.
16. Abildgaard CF. Current concepts in the management of hemophilia. Semin Hematol 1975; 12: 223-32.
17. Ashenhurst JB, Langehannig PL, Seeler RA. Early treatment of bleeding episodes with 10U/kg of factor VIII. Blood 1977; 50: 181-2.
18. Penner JA, Kelly PE. Lower doses of factor VIII for hemophilia. N Engl J Med 1977; 297: 401.
19. Weiss AE. Doses of factor VIII for hemophilic bleeding. N Engl J Med 1977; 297: 1237-8.
20. Ripa T, Scaraggi FA, Ciavarella N. Early treatment of hemophilia with minimal doses of factor VIII or factor IX. Blood 1978; 51: 763.
21. Allain JP. Dose requirement for replacement therapy in hemophilia A. Thromb Haemost 1979; 42: 825-31.
22. Stirling ML, Prescott RJ. Minimum effective dose of intermediate factor-VIII concentrate in haemophiliacs on home therapy. Lancet 1979; 1: 813-4.
23. Aronstam A, Wasssef M, Choudhury DP, Turk PM, McLellan DS. Double-blind controlled trial of three dosage regimens in treatment of haemarthroses in haemophilia A. Lancet 1980; 1: 169-71.
24. Aronstam A, Wassef M, Hamad Z, Aston DL. The identification of high-risk elbow hemorrhages in adolescents with severe hemophilia A. J Pediatr 1981; 98: 776-8.
25. Aronstam A, Wassef M, Hamad Z. Low doses of factor VIII for selected ankle bleeds in severe haemophilia A. Br Med J (Clin Res Ed) 1982; 284: 790.
26. Bray GL, Gomperts ED, Courter S et al. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood 1994; 83: 2428-35.
27. Abshire TC, Brackmann HH, Scharrer I et al. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy - International Kogenate-FS Study Group. Thromb Haemost 2000; 83: 811-6.
28. Courter SG, Bedrosian CL. Clinical evaluation of B-domain deleted recombinant factor VIII in previously treated patients. Semin Hematol 2001; 38(2 Suppl. 4): 44-51.
29. Rothschild C, Scharrer I, Brackmann HH et al. European data of a clinical trial with a sucrose formulated recombinant factor VIII in previously treated haemophilia A patients. Haemophilia 2002; 8(Suppl. 2): 10-4.
30. World Federation of Haemophilia. Guidelines for the Management of Haemophilia. Quebec: WFH publication, 2009.
31. Medical Advisory Committee of Haemophilia Foundation of New Zealand. National Guidelines - Management of Haemophilia. Wellington: Medical Advisory Committee of Haemophilia Foundation of New Zealand, 2009.
32. Gringeri A. Treatment protocol of haemophilia and other congenital bleeding disorders in Italy. Italian Association of Hemophilia Centers (AICE). Haemophilia 1998; 4: 423-4.
33. Santagostino E, Mannucci PM, Bianchi BA. Guidelines on replacement therapy for haemophilia and inherited coagulation disorders in Italy. Haemophilia 2000; 6: 1-10.
34. GREHCO (Groupe de Recherche et d'Etudes de l'Hémophilie du Centre et de l'Ouest). Le traitement de l'hémophilie. 2e Edition. Paris: Flammarion Medecine-Science, 2002.
35. Bundesärztekammer (German Medical Association). Querschnitts-Leitlinien (BAK) zur Therapie mit blutkomponenten und Plasmaderivaten (Cross-sectional Guidelines for Therapy with Blood Components and Plasma Derivatives). Deutscher Arzteverlag: Germany Bundesärztekammer, 2009: 170-8. Available in English at on 22 October 2010.
36. Berntorp E. Guidelines on treatment of haemophilia in Sweden. Haemophilia 1998; 4: 425-6.
37. Mahlangu JN, Gilham A. Guideline for the treatment of haemophilia in South Africa. S Afr Med J 2008; 98(2 Pt 2): 126-40.
38. Kasper CK. Protocols for the treatment of haemophilia and von Willebrand disease. Haemophilia 2000; 6(Suppl. 1): 84-93.
39. Srivastava A, Chuansumrit A, Chandy M, Duraiswamy G, Karagus C. Management of haemophilia in the developing world. Haemophilia 1998; 4: 474-80.
40. Elander J, Barry T. Analgesic use and pain coping among patients with haemophilia. Haemophilia 2003; 9: 202-13.
41. van Veen JJ, Gleeson DC, Makris M. Paracetamol/acetaminophen usage in haemophilia: more caution needed? Haemophilia 2008; 14: 434-5.
42. Rattray B, Nugent DJ, Young G. Celecoxib in the treatment of haemophilic synovitis, target joints, and pain in adults and children with haemophilia. Haemophilia 2006; 12: 514-7.
43. Tsoukas C, Eyster ME, Shingo S et al. Evaluation of the efficacy and safety of etoricoxib in the treatment of hemophilic arthropathy. Blood 2006; 107: 1785-90.
44. Rattray B, Nugent DJ, Young G. Rofecoxib as adjunctive therapy for haemophilic arthropathy. Haemophilia 2005; 11: 240-4.
45. Solomon SD. Cyclooxygenase-2 inhibitors and cardiovascular risk. Curr Opin Cardiol 2006; 21: 613-7.
46. Shupak R, Teitel J, Garvey MB, Freedman J. Intraarticular methylprednisolone therapy in hemophilic arthropathy. Am J Hematol 1988; 27: 26-9.
47. Kisker CT, Burke C. Management of hemarthrosis. N Engl J Med 1970; 282: 1212-3.
48. Kisker CT, Burke C. Double-blind studies on the use of steroids in the treatment of acute hemarthrosis in patients with hemophilia. N Engl J Med 1970; 282: 639-42.
49. Magistro CM. Hyaluronidase by iontophoresis in the treatment of edema. Phys Ther 1964; 44: 169-75.
50. Gandini S, Panicucci F. [Cutaneous iontophoresis of hyaluronidase in the treatment of hemorrhages in hemophilic patients]. Electrodiagn Ther 1977; 14: 99-105.
51. Costello CT, Jeske AH. Iontophoresis: applications in transdermal medication delivery. Phys Ther 1995; 75: 554-63.
52. Rodriguez-Merchan E. Articular bleeding (hemarthrosis) in haemophilia - an orthopedist's point of view. The Treatment of Haemophilia (World Federation of Haemophilia Monograph) 2008; 23: 1-11.
53. Cazenave A, Baert D, Malet T. Post-traumatic hemarthrosis of the knee and arthroscopy. Review of 161 cases. J Chir (Paris) 1990; 127: 522-7.
54. Sarimo J, Rantanen J, Heikkila J, Helttula I, Hiltunen A, Orava S. Acute traumatic hemarthrosis of the knee. Is routine arthroscopic examination necessary? A study of 320 consecutive patients. Scand J Surg 2002; 91: 361-4.
55. Kerr CB. Aspiration treatment of acute haemarthroses. Bibl Haematol 1965; 23: 1319-20.
56. Ingram GI, Mathews JA, Bennett AE. Controlled trial of joint aspiration in acute haemophilic haemarthrosis. Ann Rheum Dis 1972; 31: 423.
57. Banta JV, Boone DC, Smith CF. Arthrocentesis of the knee in acute hemophilic arthropathy. West J Med 1975; 122: 285-8.
58. Robertson JD, Connolly B, Hilliard P, Wedge J, Babyn P, Carcao M. Acute haemarthrosis of the hip joint: rapid convalescence following ultrasound-guided needle aspiration. Haemophilia 2009; 15: 390-3.
59. Gregg G. The haemophiliac joint and its treatment by physical methods. Physiotherapy 1964; 50: 394-8.
60. d'Young AI. Domiciliary application of CryoCuff in severe haemophilia: qualitative questionnaire and clinical audit. Haemophilia 2008; 14: 823-7.
61. Wilson DJ, Lardy-Smith PD, Woodham CH, MacLarnon JC. Diagnostic ultrasound in haemophilia. J Bone Joint Surg Br 1987; 69: 103-7.
62. Mauser-Bunschoten EP, Zijl JA, Mali W, van Rinsum AC, Van Den Berg HM, Roosendaal G. Successful treatment of severe bleeding in hemophilic target joints by selective angiographic embolization. Blood 2005; 105: 2654-7.
63. Klamroth R, Gottstein S, Essers E, Landgraf H, Wilaschek M, Oldenburg J. Successful angiographic embolization of recurrent elbow and knee joint bleeds in seven patients with severe haemophilia. Haemophilia 2009; 15: 247-52.
64. Donfield SM, Astermark J, Lail AE, Gilbert SA, Berntorp E. Value added: increasing the power to assess treatment outcome in joint haemorrhages. Haemophilia 2008; 14: 276-80.